Our research team has made significant breakthroughs in identifying therapeutic targets for Alzheimer's disease, including neural and immune proteins. By studying the biology and mechanisms of Alzheimer’s disease, we have recently identified soluble ST2 (sST2), a blood immune protein that plays a key role in impairing the clearance of toxic amyloid-beta in the brain. This protein is believed to be a causal factor in the development of the disease pathologies. sST2 shows promise as a therapeutic target for the development of drugs and innovative strategies to treat Alzheimer's disease. Our findings offer valuable insights into the underlying causes of the disease and present new opportunities for modulating drug screening paradigms. This will aid in the development of drug candidates for therapeutics to combat this debilitating condition.